# Iambic Therapeutics Rises 11% in Trading Debut Following $150 Million IPO

- URL: https://stocks.freetheai.org/news/iambic-therapeutics-rises-11-in-trading-debut-following-150-million-ipo-a54d8d
- Published: 2026-10-15T17:20:47Z
- Category: ipo; sentiment: bullish; impact: medium
- Symbols: [NASDAQ:IAM](https://stocks.freetheai.org/symbols/NASDAQ-IAM), [NASDAQ:NVDA](https://stocks.freetheai.org/symbols/NASDAQ-NVDA), [NYSE:ABBV](https://stocks.freetheai.org/symbols/NYSE-ABBV)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Iambic Therapeutics, Inc. (NASDAQ:IAM) gained over 10% on Thursday in its first trading session as a publicly listed firm. After pricing its initial public offering at $16.00 per share late Wednesday, the San Diego-based AI drug discovery company opened at $16.15 per share before climbing to $17.95, giving the business a market valuation of approximately $876 million. The offering of roughly 9.4 million shares targeted gross proceeds of about $150 million.

The life sciences firm is supported by prominent technology and healthcare backers, including NVIDIA Corporation (NASDAQ:NVDA) and AbbVie Inc. (NYSE:ABBV). Prior to its public debut, Iambic had raised approximately $461.8 million since its 2019 launch. Existing investors ARK Investment Management and Duquesne Family Office LLC committed to buy $60 million worth of stock at the IPO price. Iambic also established a multi-year partnership with AbbVie in September to accelerate AI-driven drug discovery across immunology, neuroscience, and oncology.

Iambic expects to generate roughly $135 million in net proceeds from the offering, which it plans to use to advance its lead drug candidate, IAM1363. The oral tyrosine kinase inhibitor is currently in Phase 1/1b clinical testing for advanced HER2-altered solid tumors, with a potentially registrational trial anticipated to start next year. Underwriters also hold a 30-day option to acquire up to 1.4 million additional shares.

## Key points

- Iambic Therapeutics priced 9.4 million shares at $16.00 per share, raising $150 million in gross proceeds.
- Shares opened at $16.15 and climbed over 10% to $17.95, giving the company a market valuation of roughly $876 million.
- The company expects $135 million in net proceeds to fund clinical trials for its lead drug candidate, IAM1363.
- Iambic is backed by Nvidia and AbbVie, with ARK Investment Management and Duquesne Family Office purchasing $60 million in IPO stock.

## Questions and answers

### What is the ticker symbol and IPO price for Iambic Therapeutics?

Iambic Therapeutics trades on the Nasdaq under the symbol IAM. The company priced its initial public offering at $16.00 per share, targeting $150 million in gross proceeds.

### Who are the major backers and investors in Iambic Therapeutics?

Iambic is backed by Nvidia and AbbVie. Existing investors, including ARK Investment Management and Duquesne Family Office LLC, agreed to purchase $60 million worth of stock at the IPO price.

### How will Iambic Therapeutics use its IPO proceeds?

Iambic expects net proceeds of about $135 million, which will primarily fund Phase 1/1b clinical trials for its lead drug asset IAM1363, an oral tyrosine kinase inhibitor for HER2-altered solid tumors.